查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1845968

全球 α 地中海貧血治療市場（按治療類型、區域範圍和預測）

Global Alpha Thalassemia Treatment Market By Treatment Type (Blood Transfusion, Chelating Therapy, Bone Marrow Transplantation), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

α-地中海型貧血治療市場規模及預測

2024 年，α地中海貧血治療市場規模價值 38 億美元，預計到 2032 年將達到 52 億美元，預測期內（2026-2032 年）的複合年成長率為 6.4%。

α地中海貧血治療市場是全球醫療保健產業的一個細分市場，專注於診斷、管理和治療α地中海貧血（一種遺傳性血液疾病）。此疾病是由負責產生α珠蛋白（血紅蛋白的主要成分）的基因突變或缺失所引起的。 α珠蛋白缺乏會導致血液中氧氣輸送減少，引發疲勞和虛弱等症狀，嚴重時還會導致貧血和器官損傷等危及生命的併發症。

市面上有多種治療選擇，包括：

頻繁輸血：這是一種常見且必要的治療方法，特別是在嚴重的情況下，以維持足夠的血紅素水平。

鐵螯合療法：用於控制鐵超載，這是頻繁輸血導致的常見併發症，可能導致器官損傷。

幹細胞移植（骨髓移植）：這被認為是治療方法嚴重的可能方法，但它是一個複雜的過程，並有相關風險。

基因治療：旨在糾正潛在的基因異常，提供長期治癒的可能性。

支持性護理：包括補充葉酸等治療以支持紅血球的生成。

市場受以下幾個關鍵因素驅動：

盛行率高：α-地中海貧血在東南亞、地中海盆地以及中東和非洲部分地區尤為普遍，患者數量眾多。

提高意識和改善診斷：大眾對遺傳性血液疾病的認知不斷提高，基因檢測和產前篩檢的進步使得人們能夠更早地進行診斷和治療。

技術進步：基因研究的突破，特別是基因治療和 CRISPR 等基因編輯技術的突破，為更有效、更少侵入性的治療開闢了新的途徑。

研究與開發：製藥和生物技術公司持續的研究與開發帶來了新藥和治療方法的開發，從而促進了市場發展。

然而，挑戰包括治療費用高昂、某些地區獲得專科護理的機會有限以及與幹細胞移植等先進治療相關的複雜性和風險。市場按治療類型、疾病類型和最終用戶（醫院、專科診所等）細分，主要參與者包括大型製藥和生物技術公司。

全球阿爾法地中海貧血治療市場促進因素

疾病盛行率不斷上升：α-地中海貧血在全球的高盛行率是導致此病患病率上升的主要因素，尤其是在東南亞、中東和地中海盆地等地區。如此龐大的患者群體使得對有效診斷和治療方案的需求日益成長。

醫療技術進步：治療和診斷領域的技術創新支撐著市場發展。這些創新包括基因治療領域的突破，例如CRISPR技術的運用，以及傳統治療方法的改進，例如骨髓移植、鐵螯合療法和輸血療法。這些進步提供了更有效、更具療癒潛力的治療方案。

認知度和醫療支出不斷提升：民眾和醫護人員對癌症的認知度不斷提升，促使人們更早診斷和尋求治療。同時，全球醫療支出的不斷成長以及政府（尤其是在發展中地區）的支持性政策，正在改善治療方案的可及性和可負擔性。

強大的研發實力：製藥和生技公司在研發方面的大量投入是推動力。這些努力正在推動候選藥物和創新治療方法的開發，包括旨在解決疾病潛在遺傳原因並改善患者預後的個人化醫療方法。

限制全球α地中海貧血治療市場的因素

治療費用高昂：治療α-地中海貧血的費用，包括終身輸血和鐵螯合療法，給患者和醫療保健系統帶來了沉重的經濟負擔。骨髓移植等治療方案較為昂貴，且大多數患者無法承受。

認知度有限，診斷挑戰重重：大眾普遍缺乏對α地中海貧血的認知，尤其是在患病率較高的地區。此病的症狀可能與其他貧血混淆，導致誤診或延遲診斷。許多國家缺乏全面且強制性的產前篩檢項目，這進一步限制了新病例的發現。

治療複雜性：重度α-地中海貧血的標準治療方案（包括定期輸血和每日鐵螯合療法）較為複雜，需要患者終身堅持。這些高要求的治療方法可能導致患者難以遵從治療，並對有效的長期治療構成挑戰。

缺乏通用治療方法：雖然骨髓移植是一種潛在的治療方法，但由於難以找到合適的捐贈者及其相關風險，其應用受到限制。基因療法等新興市場治療方法仍處於開發階段，目前市場上尚無廣泛可用、通用且無風險的治療方法。

目錄

第 1 章 α 地中海貧血治療市場介紹

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第 2 章 α 地中海貧血治療市場調查方法

  • 資料探勘
  • 二次調查
  • 初步調查
  • 專家建議
  • 品質檢查
  • 最終審核
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 資料來源

3. α地中海貧血治療市場執行摘要

  • 全球阿爾法地中海貧血治療市場概覽
  • 全球α地中海貧血治療市場的估計與預測
  • 阿爾法血球減少症治療藥物的全球市場生態圖譜
  • 競爭分析漏斗圖
  • 全球阿爾法地中海貧血治療市場絕對商機
  • 全球α-地中海貧血治療市場吸引力分析（按地區）
  • 全球 α 地中海貧血治療市場吸引力分析（按類型）
  • 全球 α 地中海貧血治療市場吸引力分析（按最終用戶）
  • 全球阿爾法地中海貧血治療市場區域分析（CAGR）
  • 全球α地中海貧血治療市場（按類型）
  • 全球α地中海貧血治療市場（以最終用戶分類）
  • 全球α-地中海貧血治療市場（按地區）
  • 未來市場機遇

第4章 α地中海型貧血治療市場展望

  • 全球α地中海貧血治療市場的變化
  • 全球阿爾法血症治療市場前景
  • 市場促進因素
  • 市場限制
  • 市場趨勢
  • 市場機遇
  • 波特五力分析
    • 新進入者的威脅
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 現有競爭對手之間的敵意
  • 價值鏈分析
  • 定價分析
  • 宏觀經濟分析

5. 阿爾法地中海貧血治療市場（依治療類型）

  • 概述
  • 輸血治療
  • 螯合療法
  • 骨髓移植

6. 阿爾法地中海貧血治療市場（依最終用戶分類）

  • 概述
  • 醫院
  • 專科診所
  • 研究所
  • 家庭醫療保健

7. α-地中海貧血治療市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

第 8 章：α 地中海貧血治療市場的競爭格局

  • 概述
  • 主要發展策略
  • 公司地理分佈
  • 王牌矩陣
    • 積極的
    • 前線
    • 新興
    • 創新者

9. 阿爾法地中海貧血治療市場公司簡介

  • 概述
  • 諾華
  • 新基公司
  • 藍鳥生物
  • Accelon
  • 丹納赫公司
  • 夏爾公司
Product Code: 12132

Alpha Thalassemia Treatment Market Size And Forecast

Alpha Thalassemia Treatment Market size was valued at USD 3.8 Billion in 2024 and is projected to reach USD 5.2 Billion by 2032, growing at a CAGR of 6.4% during the forecast period 2026-2032.

The Alpha Thalassemia Treatment Market is a segment of the global healthcare industry focused on the diagnosis, management, and treatment of alpha thalassemia, an inherited blood disorder. This condition is caused by a genetic mutation or deletion in the genes responsible for producing alpha globin, a key component of hemoglobin. The deficiency in alpha globin leads to reduced oxygen transport in the blood, causing symptoms like fatigue and weakness, and in severe cases, life threatening complications like anemia and organ damage.

The market encompasses a range of therapeutic options, including:

Frequent Blood Transfusions: A common and essential treatment, particularly for severe cases, to maintain adequate hemoglobin levels.

Iron Chelation Therapy: Used to manage iron overload, a common complication resulting from frequent blood transfusions, which can lead to organ damage.

Stem Cell Transplant (Bone Marrow Transplant): Considered a potential cure for severe forms of the disease, though it is a complex procedure with associated risks.

Gene Therapy: An emerging and promising area of the market that aims to correct the underlying genetic defects, offering the potential for a long term, curative solution.

Supportive Therapies: This includes treatments like folic acid supplements to support red blood cell production.

The market is driven by several key factors:

High Prevalence: Alpha thalassemia is particularly prevalent in regions like Southeast Asia, the Mediterranean, the Middle East, and parts of Africa, creating a substantial patient population.

Increased Awareness and Improved Diagnostics: Rising public awareness about inherited blood disorders, along with advancements in genetic testing and prenatal screening, are leading to earlier diagnosis and treatment.

Technological Advancements: Breakthroughs in genetic research, particularly in gene therapy and gene editing technologies like CRISPR, are opening new avenues for more effective and less invasive treatments.

Research and Development: Ongoing R&D by pharmaceutical and biotech companies is leading to the development of novel drugs and therapies, contributing to market growth.

However, the market also faces challenges, including the high cost of treatment, limited access to specialized care in some regions, and the complexities and risks associated with advanced therapies like stem cell transplants. The market is segmented by treatment type, disease type, and end users (hospitals, specialty clinics, etc.), with key players including major pharmaceutical and biotechnology companies.

Global Alpha Thalassemia Treatment Market Drivers

Increasing Prevalence of the Disease: A significant driver is the high global prevalence of thalassemia, including its alpha variant, particularly in regions such as Southeast Asia, the Middle East, and the Mediterranean. This substantial patient population creates a constant and growing demand for effective diagnostic and therapeutic solutions.

Advancements in Medical Technology: The market is propelled by technological innovations in treatment and diagnosis. This includes breakthroughs in gene therapy, such as the use of CRISPR technology, as well as improvements in traditional treatments like bone marrow transplants, iron chelation therapies, and blood transfusions. These advancements offer more effective and potentially curative options.

Growing Awareness and Healthcare Expenditure: Rising awareness of the disease among both the public and healthcare professionals is leading to earlier diagnosis and treatment seeking behavior. Concurrently, increasing healthcare expenditure globally, particularly in developing regions, and supportive government policies are improving access to and affordability of treatment options.

Robust Research and Development: Significant investments in research and development by pharmaceutical and biotechnology companies are a major driver. These efforts are leading to the development of new drug candidates and innovative therapies, including personalized medicine approaches, aimed at addressing the underlying genetic causes of the disease and improving patient outcomes.

Global Alpha Thalassemia Treatment Market Restraints

High Cost of Treatment: The cost of therapies for alpha thalassemia, including lifelong blood transfusions and iron chelation, is a significant financial burden for patients and healthcare systems. Curative options like bone marrow transplants are even more expensive and not accessible to the majority of the patient population.

Limited Awareness and Diagnostic Challenges: There is a widespread lack of public awareness about alpha thalassemia, especially in regions with a high prevalence of the disease. The symptoms can be confused with other forms of anemia, leading to misdiagnosis or delayed diagnosis. The absence of comprehensive and mandatory prenatal screening programs in many countries further limits the identification of new cases.

Complexity of Management: The standard treatments for severe alpha thalassemia, such as regular blood transfusions and daily iron chelation therapy, are complex and require a lifelong commitment from the patient. This demanding treatment regimen can lead to patient non adherence and poses a challenge for effective long term management.

Lack of a Universal Cure: While bone marrow transplant is a potential cure, its use is restricted due to the difficulty in finding a compatible donor and the associated risks. Advanced therapies like gene therapy are still in development and clinical trials, meaning there is no widely available, universal, and risk free cure for the disease on the market.

Global Alpha Thalassemia Treatment Market Segmentation Analysis

The Global Alpha Thalassemia Treatment Market is Segmented on the basis of Type of Treatment Type, End-User, and, Geography.

Alpha Thalassemia Treatment Market By Treatment Type

Blood Transfusion

Chelating Therapy

Bone Marrow Transplantation

Based on Treatment Type, the Alpha Thalassemia Treatment Market is segmented into Blood Transfusion, Chelating Therapy, and Bone Marrow Transplantation. At VMR, we observe that the Blood Transfusion subsegment holds the dominant market share, primarily due to its widespread and long standing use as a foundational treatment for moderate to severe forms of the disease. This dominance is driven by several key factors, including its immediate efficacy in alleviating anemia symptoms and improving quality of life for transfusion dependent patients. The market for this segment is fueled by the high prevalence of alpha thalassemia, particularly in the Asia Pacific and Middle East & Africa regions, where large patient populations rely on this readily available and relatively cost effective therapy.

Furthermore, advancements in blood screening and transfusion protocols have enhanced safety and reduced complications, contributing to its sustained adoption across a wide range of healthcare settings, from large hospitals to smaller clinics. Following closely, Chelating Therapy represents the second most dominant subsegment, serving a crucial role in managing the iron overload that is a direct consequence of frequent blood transfusions. This subsegment's growth is directly tied to the Blood Transfusion segment, as it is a necessary supportive therapy to prevent long term organ damage, particularly to the heart and liver. The increasing awareness of the risks associated with iron overload, coupled with the introduction of new, more convenient oral chelating agents, is driving its growth. Geographically, its demand is strongest in regions with high transfusion rates, and its market is supported by a steady flow of research and development aimed at improving drug adherence and efficacy. Finally, Bone Marrow Transplantation and other emerging treatments like gene therapy, while representing a smaller market share, hold significant future potential. These segments are gaining traction as a potential cure for the disease, though their adoption is currently limited by high costs, the challenge of finding suitable donors, and the need for specialized medical infrastructure. Their growth is supported by ongoing clinical trials and technological advancements, which are gradually improving their safety and accessibility, positioning them as a transformative, albeit niche, market for curative treatment.

Alpha Thalassemia Treatment Market By End-User

Hospitals

Specialty Clinics

Research Institutes

Home Healthcare

Based on End User, the Alpha Thalassemia Treatment Market is segmented into Hospitals, Specialty Clinics, Research Institutes, and Home Healthcare. At VMR, we have consistently observed that the Hospitals subsegment holds the dominant market share. This dominance is a result of several critical factors. Hospitals are the primary destination for patients with severe forms of alpha thalassemia, such as Hemoglobin H disease or Hydrops Fetalis, which require frequent and complex interventions like regular blood transfusions and bone marrow transplantation. The robust infrastructure, availability of specialized equipment, and multidisciplinary teams including hematologists, transfusion specialists, and nurses, are essential for managing these high acuity cases. Moreover, global health trends show that rising healthcare expenditures and government initiatives, particularly in high prevalence regions like Asia Pacific and the Middle East, are strengthening hospital capacities to handle chronic genetic disorders. For instance, data from our recent analyses indicates that hospitals account for over 50% of the revenue contribution in the broader thalassemia treatment market.

The second most dominant subsegment is Specialty Clinics. These facilities are gaining traction by offering a focused, patient centric approach to care. Their growth is propelled by the increasing demand for specialized, long term management of thalassemia, including iron chelation therapy and ongoing monitoring. These clinics provide a more personalized and convenient experience for patients who require routine but less acute care, alleviating some of the burden from hospitals. This trend is particularly strong in North America and Europe, where well established healthcare systems support the proliferation of these specialized centers.

The remaining subsegments, Research Institutes and Home Healthcare, play a crucial, albeit supporting, role. Research Institutes are vital for the future of alpha thalassemia treatment, as they are at the forefront of developing innovative and curative therapies like gene therapy and CRISPR based treatments. While their revenue contribution is minimal, their impact on future market dynamics and the long term outlook for the disease is immense. Home Healthcare, on the other hand, represents a niche but growing area, primarily for the administration of certain iron chelation therapies and remote patient monitoring, offering a convenience factor that will likely see increased adoption as technology and telehealth services advance.

Alpha Thalassemia Treatment Market By Geography

North America

Europe

Asia-Pacific

South America

Middle East & Africa

The global alpha thalassemia treatment market exhibits distinct dynamics across different regions, driven by a combination of disease prevalence, healthcare infrastructure, and the adoption of advanced therapies. While traditional treatments like blood transfusions and iron chelation therapy remain the cornerstone of care worldwide, the market is being reshaped by advancements in genetic testing and the emergence of curative gene therapies, albeit with significant regional variations in accessibility and market penetration.

United States Alpha Thalassemia Treatment Market

The U.S. market is a dominant force, characterized by a highly advanced healthcare system, significant research and development investments, and a favorable regulatory environment. The primary drivers are the high spending on healthcare, a growing focus on rare diseases, and the presence of leading biopharmaceutical companies. The market benefits from strong research initiatives, including a robust pipeline for gene and stem cell therapies, with some of the first curative treatments for related conditions like beta thalassemia receiving FDA approval. This has positioned the U.S. at the forefront of innovation, leading to a high adoption rate of novel therapies. However, the market is also defined by the extremely high cost of these advanced treatments, which can pose a challenge for patient access despite strong insurance coverage and reimbursement models.

Europe Alpha Thalassemia Treatment Market:

Europe represents a mature market with a high degree of awareness and well established healthcare systems. The market is driven by increasing diagnostic capabilities through genetic testing and screening programs, particularly in Mediterranean countries where the disease is more prevalent. Government initiatives and a focus on patient centric care models contribute to the market's stability and growth. While traditional treatments are widely accessible, the region is also seeing the gradual adoption of advanced therapies. Regulatory bodies like the European Medicines Agency (EMA) play a key role in approving new drugs, and collaborations between research institutes and pharmaceutical companies are accelerating the development of innovative treatments. The market faces a restraint in the form of fragmented healthcare systems and varying reimbursement policies across different countries, which can affect the speed of new drug adoption.

Asia Pacific Alpha Thalassemia Treatment Market:

The Asia Pacific region is a major hub for the alpha thalassemia market and is projected to experience the fastest growth. This is primarily due to the exceptionally high prevalence of the disease, particularly in Southeast Asia and parts of China and India. The key growth drivers include rising healthcare expenditures, a large and increasing patient population, and improving healthcare infrastructure. As awareness grows and diagnostic capabilities become more accessible, a larger number of cases are being diagnosed and treated. While cost remains a significant barrier for many patients, supportive government initiatives and non profit organizations are working to improve access to essential treatments. The market is characterized by a high reliance on standard treatments, but there is also a growing investment in research and development, suggesting a promising future for the adoption of more advanced therapies.

Latin America Alpha Thalassemia Treatment Market:

The Latin American market is a developing but important segment. The market dynamics are largely influenced by a combination of increasing disease awareness and healthcare improvements, coupled with significant economic disparities. While some countries have made strides in establishing specialized thalassemia treatment centers, access to advanced therapies remains limited. The market is driven by the need for more affordable and accessible treatments. Blood transfusion and iron chelation therapies are the primary modes of treatment. Challenges include a lack of widespread screening programs, which leads to under diagnosis, and a healthcare infrastructure that is not uniformly equipped to handle the long term, complex management of the disease. Growth in this region is expected to be steady but constrained by economic limitations and the high cost of new, patented drugs.

Middle East & Africa Alpha Thalassemia Treatment Market:

The Middle East and Africa region presents a complex market landscape. The Middle East, particularly countries with advanced healthcare systems like Saudi Arabia and the UAE, is making significant investments in genetic screening and specialized care, driven by a high prevalence rate. The market here is growing due to a rising patient population and government support for rare disease treatments. In contrast, the African market faces major challenges. While the prevalence of the alpha thalassemia trait is high, particularly in sub Saharan Africa, the market is severely restrained by a lack of awareness, limited diagnostic capabilities, and an underdeveloped healthcare infrastructure. Access to basic treatments is a major hurdle. Efforts from international health organizations and local governments are focused on establishing basic screening and care programs, but widespread adoption of advanced treatments like gene therapy is still a distant prospect.

Key Players

  • The major players in the Alpha Thalassemia Treatment Market are:
  • Novartis AG
  • Celgene Corporation
  • Bluebird Bio, Inc.
  • Acceleron Pharma, Inc.
  • Danaher Corporation
  • Shire Plc.

TABLE OF CONTENTS

1 INTRODUCTION OF ALPHA THALASSEMIA TREATMENT MARKET

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 ALPHA THALASSEMIA TREATMENT MARKET RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 DATA SOURCES

3 ALPHA THALASSEMIA TREATMENT MARKET EXECUTIVE SUMMARY

  • 3.1 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET OVERVIEW
  • 3.2 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET ESTIMATES AND FORECAST (USD BILLION)
  • 3.3 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET ECOLOGY MAPPING
  • 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
  • 3.5 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET ABSOLUTE MARKET OPPORTUNITY
  • 3.6 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY REGION
  • 3.7 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY TYPE
  • 3.8 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET ATTRACTIVENESS ANALYSIS, BY END-USER
  • 3.9 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.10 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET, BY TYPE (USD BILLION)
  • 3.11 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET, BY END-USER (USD BILLION)
  • 3.12 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET, BY GEOGRAPHY (USD BILLION)
  • 3.13 FUTURE MARKET OPPORTUNITIES

4 ALPHA THALASSEMIA TREATMENT MARKET OUTLOOK

  • 4.1 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET EVOLUTION
  • 4.2 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET OUTLOOK
  • 4.3 MARKET DRIVERS
  • 4.4 MARKET RESTRAINTS
  • 4.5 MARKET TRENDS
  • 4.6 MARKET OPPORTUNITY
  • 4.7 PORTER'S FIVE FORCES ANALYSIS
    • 4.7.1 THREAT OF NEW ENTRANTS
    • 4.7.2 BARGAINING POWER OF SUPPLIERS
    • 4.7.3 BARGAINING POWER OF BUYERS
    • 4.7.4 THREAT OF SUBSTITUTE TYPES
    • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
  • 4.8 VALUE CHAIN ANALYSIS
  • 4.9 PRICING ANALYSIS
  • 4.10 MACROECONOMIC ANALYSIS

5 ALPHA THALASSEMIA TREATMENT MARKET, BY TREATMENT TYPE

  • 5.1 OVERVIEW
  • 5.2 BLOOD TRANSFUSION
  • 5.3 CHELATING THERAPY
  • 5.4 BONE MARROW TRANSPLANTATION

6 ALPHA THALASSEMIA TREATMENT MARKET, BY END-USER

  • 6.1 OVERVIEW
  • 6.2 HOSPITALS
  • 6.3 SPECIALTY CLINICS
  • 6.4 RESEARCH INSTITUTES
  • 6.5 HOME HEALTHCARE

7 ALPHA THALASSEMIA TREATMENT MARKET, BY GEOGRAPHY

  • 7.1 OVERVIEW
  • 7.2 NORTH AMERICA
    • 7.2.1 U.S.
    • 7.2.2 CANADA
    • 7.2.3 MEXICO
  • 7.3 EUROPE
    • 7.3.1 GERMANY
    • 7.3.2 U.K.
    • 7.3.3 FRANCE
    • 7.3.4 ITALY
    • 7.3.5 SPAIN
    • 7.3.6 REST OF EUROPE
  • 7.4 ASIA PACIFIC
    • 7.4.1 CHINA
    • 7.4.2 JAPAN
    • 7.4.3 INDIA
    • 7.4.4 REST OF ASIA PACIFIC
  • 7.5 LATIN AMERICA
    • 7.5.1 BRAZIL
    • 7.5.2 ARGENTINA
    • 7.5.3 REST OF LATIN AMERICA
  • 7.6 MIDDLE EAST AND AFRICA
    • 7.6.1 UAE
    • 7.6.2 SAUDI ARABIA
    • 7.6.3 SOUTH AFRICA
    • 7.6.4 REST OF MIDDLE EAST AND AFRICA

8 ALPHA THALASSEMIA TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 8.1 OVERVIEW
  • 8.2 KEY DEVELOPMENT STRATEGIES
  • 8.3 COMPANY REGIONAL FOOTPRINT
  • 8.4 ACE MATRIX
    • 8.5.1 ACTIVE
    • 8.5.2 CUTTING EDGE
    • 8.5.3 EMERGING
    • 8.5.4 INNOVATORS

9 ALPHA THALASSEMIA TREATMENT MARKET COMPANY PROFILES

  • 9.1 OVERVIEW
  • 9.2 NOVARTIS AG
  • 9.3 CELGENE CORPORATION
  • 9.4 BLUEBIRD BIO, INC.
  • 9.5 ACCELERON PHARMA, INC.
  • 9.6 DANAHER CORPORATION
  • 9.7 SHIRE PLC.

LIST OF TABLES AND FIGURES

  • TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 4 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 5 GLOBAL ALPHA THALASSEMIA TREATMENT MARKET, BY GEOGRAPHY (USD BILLION)
  • TABLE 6 NORTH AMERICA ALPHA THALASSEMIA TREATMENT MARKET, BY COUNTRY (USD BILLION)
  • TABLE 7 NORTH AMERICA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 9 NORTH AMERICA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 10 U.S. ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 12 U.S. ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 13 CANADA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 15 CANADA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 16 MEXICO ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 18 MEXICO ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 19 EUROPE ALPHA THALASSEMIA TREATMENT MARKET, BY COUNTRY (USD BILLION)
  • TABLE 20 EUROPE ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 21 EUROPE ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 22 GERMANY ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 23 GERMANY ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 24 U.K. ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 25 U.K. ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 26 FRANCE ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 27 FRANCE ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 28 ALPHA THALASSEMIA TREATMENT MARKET , BY USER TYPE (USD BILLION)
  • TABLE 29 ALPHA THALASSEMIA TREATMENT MARKET , BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 30 SPAIN ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 31 SPAIN ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 32 REST OF EUROPE ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 33 REST OF EUROPE ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 34 ASIA PACIFIC ALPHA THALASSEMIA TREATMENT MARKET, BY COUNTRY (USD BILLION)
  • TABLE 35 ASIA PACIFIC ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 36 ASIA PACIFIC ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 37 CHINA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 38 CHINA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 39 JAPAN ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 40 JAPAN ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 41 INDIA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 42 INDIA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 43 REST OF APAC ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 44 REST OF APAC ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 45 LATIN AMERICA ALPHA THALASSEMIA TREATMENT MARKET, BY COUNTRY (USD BILLION)
  • TABLE 46 LATIN AMERICA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 47 LATIN AMERICA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 48 BRAZIL ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 49 BRAZIL ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 50 ARGENTINA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 51 ARGENTINA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 52 REST OF LATAM ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 53 REST OF LATAM ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 54 MIDDLE EAST AND AFRICA ALPHA THALASSEMIA TREATMENT MARKET, BY COUNTRY (USD BILLION)
  • TABLE 55 MIDDLE EAST AND AFRICA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 56 MIDDLE EAST AND AFRICA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 57 UAE ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 58 UAE ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 59 SAUDI ARABIA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 60 SAUDI ARABIA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 61 SOUTH AFRICA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 62 SOUTH AFRICA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 63 REST OF MEA ALPHA THALASSEMIA TREATMENT MARKET, BY USER TYPE (USD BILLION)
  • TABLE 64 REST OF MEA ALPHA THALASSEMIA TREATMENT MARKET, BY PRICE SENSITIVITY (USD BILLION)
  • TABLE 65 COMPANY REGIONAL FOOTPRINT